<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37804440</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1437-2320</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Neurosurgical review</Title><ISOAbbreviation>Neurosurg Rev</ISOAbbreviation></Journal><ArticleTitle>Primary intracranial lymphomas-incidence and survival: a population-based study.</ArticleTitle><Pagination><StartPage>265</StartPage><MedlinePgn>265</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10143-023-02172-4</ELocationID><Abstract><AbstractText>Biopsy is recommended for patients with primary intracranial lymphoma to confirm the diagnosis, but the effect of tumor resection is still controversial. We conducted this retrospective study to better understand the epidemiology of primary intracranial lymphoma in the USA and explore the relationship between surgical resection and prognosis. Data regarding primary intracranial lymphoma, including incidence, were extracted from the SEER database. We analyzed the difference in incidence between different groups of people. We explored the effect of surgery on the survival of patients by the Kaplan-Meier method and evaluated the possible prognostic indicators by multivariate Cox proportional hazards models. The incidence significantly increased with age. The non-Hispanic Asian or Pacific Islander population exhibited the highest incidence, and the incidence was significantly higher in males than females. A total of 6428 cases were included in the cohort study, and most of the patients were diagnosed in the sixth to seventh decade of life. Sixty percent of tumors were supratentorial tumors. Surgery, especially total resection, significantly improved overall survival and cancer-specific survival. The survival of female patients, patients diagnosed before reaching 60 years of age, patients diagnosed after 2010, and patients with supratentorial lymphomas was better than that of their counterparts. The survival of patients with diffuse large B-cell lymphoma was worse than that of their counterparts. We conducted a comprehensive retrospective analysis of patients with primary intracranial lymphoma. We analyzed the difference in incidence between different groups of people. Surgery significantly improved overall and cancer-specific survival. The results of our research can help clinicians and patients better understand the epidemiology and management of primary intracranial lymphoma.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yining</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xiangyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, First Hospital of Jilin University, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Taikun</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Pu</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yubo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, Jilin, People's Republic of China. wangyubo@jlu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Neurosurg Rev</MedlineTA><NlmUniqueID>7908181</NlmUniqueID><ISSNLinking>0344-5607</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018426" MajorTopicYN="N">SEER Program</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016403" MajorTopicYN="Y">Lymphoma, Large B-Cell, Diffuse</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CNS Disease</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Lymphoma</Keyword><Keyword MajorTopicYN="N">SEER Program</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37804440</ArticleId><ArticleId IdType="doi">10.1007/s10143-023-02172-4</ArticleId><ArticleId IdType="pii">10.1007/s10143-023-02172-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grommes C, DeAngelis LM (2017) Primary CNS Lymphoma. J Clin Oncol 35(21):2410&#x2013;2418</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2017.72.7602</ArticleId><ArticleId IdType="pubmed">28640701</ArticleId><ArticleId IdType="pmc">5516483</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox CP, Phillips EH, Smith J, Linton K, Gallop-Evans E, Hemmaway C, Auer DP, Fuller C, Davies AJ, McKay P et al (2019) Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol 184(3):348&#x2013;363</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.15661</ArticleId><ArticleId IdType="pubmed">30467845</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, Grommes C (2018) The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol 20(5):687&#x2013;694</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/nox187</ArticleId><ArticleId IdType="pubmed">29036697</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L, Pawlish K, Yanik EL, Suneja G, Engels EA (2016) Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol 174(3):417&#x2013;424</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.14073</ArticleId><ArticleId IdType="pubmed">27018254</ArticleId><ArticleId IdType="pmc">4961566</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Ruda R, Schlegel U, Siegal T, Soussain C, Abacioglu U et al (2015) Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 16(7):e322&#x2013;e332</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(15)00076-5</ArticleId><ArticleId IdType="pubmed">26149884</ArticleId></ArticleIdList></Reference><Reference><Citation>Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT (2019) Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol 21(3):296&#x2013;305</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noy192</ArticleId><ArticleId IdType="pubmed">30418592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosee PL, Schorb E et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3(5):e217&#x2013;e227</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(16)00036-3</ArticleId><ArticleId IdType="pubmed">27132696</ArticleId></ArticleIdList></Reference><Reference><Citation>Rae AI, Mehta A, Cloney M, Kinslow CJ, Wang TJC, Bhagat G, Canoll PD, Zanazzi GJ, Sisti MB, Sheth SA et al (2019) Craniotomy and survival for primary central nervous system lymphoma. Neurosurgery 84(4):935&#x2013;944</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuros/nyy096</ArticleId><ArticleId IdType="pubmed">29660011</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller M, Martus P, Roth P, Thiel E, Korfel A, German PSG (2012) Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 14(12):1481&#x2013;1484</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/nos159</ArticleId><ArticleId IdType="pubmed">22984018</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarabay A, Cossu G, Berhouma M, Levivier M, Daniel RT, Messerer M (2016) Primary pituitary lymphoma: an update of the literature. J Neurooncol 130(3):383&#x2013;395</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11060-016-2249-z</ArticleId><ArticleId IdType="pubmed">27581598</ArticleId></ArticleIdList></Reference><Reference><Citation>Overview of the SEER Program. https://seer.cancer.gov/about/overview.html . Accessed 9 Sept 2022</Citation></Reference><Reference><Citation>Surveillance, Epidemiology, and End Results (SEER) Program ( www.seer.cancer.gov ) SEER*Stat Database: Incidence - SEER Research Plus Data, 18 Registries, Nov 2020 Sub (2000-2018) - Linked To County Attributes - Total U.S., 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission</Citation></Reference><Reference><Citation>Surveillance, Epidemiology, and End Results (SEER) Program ( www.seer.cancer.gov ) SEER*Stat Database: Incidence - SEER Research Data, 18 Registries, Nov 2020 Sub (2000-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission</Citation></Reference><Reference><Citation>Ichikawa T, Shimojima Y, Kishida D, Kaneko T, Sekijima Y (2021) Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: case-based review. Rheumatol Int 41(5):1009&#x2013;1017</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04569-6</ArticleId><ArticleId IdType="pubmed">32253501</ArticleId></ArticleIdList></Reference><Reference><Citation>Holdhoff M, Mrugala MM, Grommes C, Kaley TJ, Swinnen LJ, Perez-Heydrich C, Nayak L (2020) Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma. J Natl Compr Canc Netw 18(11):1571&#x2013;1578</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2020.7667</ArticleId><ArticleId IdType="pubmed">33152700</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayuso-Peralta L, Orti-Pareja M, Zurdo-Hernandez M, Jimenez-Jimenez FJ, Tejeiro-Martinez J, Ricoy JR, de la Lama A, Bernardo AI (2001) Cerebral lymphoma presenting as a leukoencephalopathy. J Neurol Neurosurg Psychiatry 71(2):243&#x2013;246</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.71.2.243</ArticleId><ArticleId IdType="pubmed">11459903</ArticleId><ArticleId IdType="pmc">1737531</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97&#x2013;109</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0243-4</ArticleId><ArticleId IdType="pubmed">17618441</ArticleId><ArticleId IdType="pmc">1929165</ArticleId></ArticleIdList></Reference><Reference><Citation>Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105(9):1414&#x2013;1418</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2011.357</ArticleId><ArticleId IdType="pubmed">21915121</ArticleId><ArticleId IdType="pmc">3241537</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Garzon-Muvdi T, Braileanu M, Porras JL, Caplan JM, Rong X, Huang J, Jallo GI (2017) Primary intramedullary spinal cord lymphoma: a population-based study. Neuro Oncol 19(3):414&#x2013;421</Citation><ArticleIdList><ArticleId IdType="pubmed">28011925</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24(36):5711&#x2013;5715</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2006.08.2941</ArticleId><ArticleId IdType="pubmed">17116938</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Wang L, Hu J, Qian W, Zhang X, Hu Y, Zhu Q, Chen B, Wu D, Chang CH et al (2021) Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China. Cancer Commun (London, England) 41(3):229&#x2013;239</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cac2.12126</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol 22(12 Suppl 2):iv1&#x2013;iv96</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noaa200</ArticleId><ArticleId IdType="pubmed">33123732</ArticleId><ArticleId IdType="pmc">7596247</ArticleId></ArticleIdList></Reference><Reference><Citation>Bierman PJ (2014) Surgery for primary central nervous system lymphoma: is it time for reevaluation? Oncology (Williston Park, NY) 28(7):632&#x2013;637</Citation></Reference><Reference><Citation>Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31(25):3061&#x2013;3068</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2012.46.9957</ArticleId><ArticleId IdType="pubmed">23569323</ArticleId><ArticleId IdType="pmc">3753699</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahr G, Da Broi M, Holte H Jr, Beiske K, Meling TR (2018) The role of surgery in intracranial PCNSL. Neurosurg Rev 41(4):1037&#x2013;1044</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10143-018-0946-0</ArticleId><ArticleId IdType="pubmed">29383600</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>